Abstract
Squamous cell carcinoma (SCC) is the second most common skin cancer worldwide and, despite the relatively easy visualization of the tumor in the clinic, a sizeable number of SCC patients are diagnosed at advanced stages with local invasion and distant metastatic lesions. In the last decade, immunotherapy has emerged as the fourth pillar in cancer therapy via the targeting of immune checkpoint molecules such as programmed cell-death protein-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). FDA-approved monoclonal antibodies directed against these immune targets have provide survival benefit in a growing list of cancer types. Currently, there are two immunotherapy drugs available for cutaneous SCC: cemiplimab and pembrolizumab; both monoclonal antibodies (mAb) that block PD-1 thereby promoting T-cell activation and/or function. However, the success rate of these checkpoint inhibitors currently remains around 50%, which means that half of the patients with advanced SCC experience no benefit from this treatment. This review will highlight the mechanisms by which the immune checkpoint molecules regulate the tumor microenvironment (TME), as well as the ongoing clinical trials that are employing single or combinatory therapeutic approaches for SCC immunotherapy. We also discuss the regulation of additional pathways that might promote superior therapeutic efficacy, and consequently provide increased survival for those patients that do not benefit from the current checkpoint inhibitor therapies.
Introduction
Squamous cell carcinoma (SCC) is the second most common skin cancer worldwide and, despite the relatively easy visualization of the tumor in the clinic, a sizeable number of SCC patients are diagnosed at advanced stages with local invasion and distant metastatic lesions (Tromp et al., 2005). Worldwide, 300,000 new cases are seen each year (Thomson, 2018; Stang et al., 2019). The most significant risk factor for SCC includes sun exposure and age and is most common in white male individuals (Que et al., 2018a). Microscopically, SCC can be subcategorized according to the differentiation status of the epithelium and the presence of metastatic lesions (Que et al., 2018a). Tumor diameter and perineural involvement are highly associated with mortality risk (Que et al., 2018a). The majority of cutaneous SCC can be surgically removed, however, high risk and advanced SCC management remained to be standardized (Que et al., 2018b).
The high risk of SCC development observed in immunocompromised individuals highlights the critical role of the immune system during skin carcinogenesis (Euvrard et al., 2003; Asgari et al., 2017; Omland et al., 2018). Conversely, increased infiltration of specific inflammatory cells, such as neutrophils, macrophages, and T lymphocytes are associated with aggressive SCC and metastasis (Duan et al., 2000; Seddon et al., 2016; Jiang et al., 2019). Such discordant observations are explained by the great capacity of tumor cells to modulate the tumor microenvironment (TME) to become a supportive niche thereby inhibiting anti-tumoral responses (Weber et al., 2005; Moussai et al., 2011; Maalouf et al., 2012). The CD28-related inhibitory receptors crucial for T cell regulation, namely cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell-death protein-1 (PD-1), are highly expressed in human SCC samples and associated with cancer progression (Welsh et al., 2009; Gambichler et al., 2017). Blocking specific immunosuppressive pathways seems to be the most promising approach to fight cancer cells. Indeed, PD-1 blockade using monoclonal antibody has been shown to increase the infiltration of CD4+ and CD8+ T cells and delays SCC development in mice (Belai et al., 2014), and the immunotherapy that blocks the signaling pathway mediated by PD-1 has been approved for cutaneous SCC. However, a significant proportion of SCC patients receive no benefit from this therapy (Migden et al., 2018). Such observations highlight the need for developing alternative or combinatory targets, that take into account the complexity of the immune system and the heterogeneity of tumor-infiltrating leukocytes in SCC (Ji et al., 2020). For example, regulatory T cells (Tregs) are observed in advanced cancers and also associated with poor outcomes (Azzimonti et al., 2015). Pre-clinical model of SCC development is also accompanied by infiltration of Tregs in the skin and draining lymph nodes (LN), and depletion of these cells using anti-CD25 significantly impaired SCC progression by increasing the infiltration of activated CD4+ and CD8+ T cells in the TME and the production of anti-tumor cytokines such as IL-12 and IFN-γ (Ramos et al., 2012). Herein, we provide a comprehensive overview of the interactions between tumor and immune cells and highlight strategies to identify potential new targets and biomarkers for immunotherapy in SCC.
Cellular Composition of the Tumor Microenvironment
The SCC microenvironment is comprised of cancerous and normal epithelial cells, fibroblasts, endothelial cells (ECs), melanocytes, plasmacytoid, and dendritic cells (DCs), Langerhans cells, macrophages, myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, CD4+ and CD8+ T cells, and Tregs (Ji et al., 2020). Importantly, the frequency of each cell type varies considerably between patients, suggesting that the TME is not static and might be influenced by genetic and other patient-derived intrinsic factors (Ji et al., 2020). The role of the TME during SCC tumorigenesis and the mechanisms of immune escape are summarized in Figure 1.
FIGURE 1
The stroma adjacent to SCC is composed mainly of ECs and fibroblasts that create a fibrovascular niche (Ji et al., 2020). The association between ECs and cancer is frequently studied since angiogenesis is fundamental for SCC development (Tonini et al., 2003; Florence et al., 2011; Figure 1A). In addition, it has been demonstrated that tumor cell increased the expression of CD200 in ECs, which in combination with its ligand, CD200R (present in macrophages and DCs), might be a mechanism leading to immunosuppression in the TME (Belkin et al., 2013; Figure 1A). Fibroblasts are highly heterogeneous and multifunctional mesenchymal-derived cells embedded within the interstitial extracellular matrix that becomes activated during wound healing, tissue inflammation, and organ fibrosis (Chen and Song, 2019). Activated fibroblasts in the TME are named cancer-associated fibroblasts (CAFs) and are identified by the expression of α-smooth muscle actin (α–SMA), fibroblast-activation protein α (FAPα), and ferroptosis suppressor protein 1 (FSP-1) (Öhlund et al., 2014). CAFs directly impact the behavior of tumor cells by increasing the expression of laminin-332 γ2 chain in tumor cells through activation of the TGF-β signaling subsequently leading to enhanced cell invasion (Siljamäki et al., 2020; Figure 1B). CAFs also have a role in immunosurveillance and tumor escape via CD276 (B7-H3), which augments Tregs and inhibit cytotoxic CD8+ T cell responses (Ji et al., 2020) and promote tumor development by enhancing monocyte chemoattractant protein-1 (MCP-1)–dependent macrophage infiltration and chronic inflammation (Zhang et al., 2011; Figure 1B). However, Zhang et al. (2013a) demonstrated that CAFs can prevent carcinogen-derived tumor formation by protecting epithelial cells from DNA damage, suggesting an ambiguous role of CAFs in cutaneous SCC.
During inflammation, neutrophils are among the first phagocytes to infiltrate the tissue, mostly through CXC chemokine-mediated chemotaxis, and these cells predominate in the SCC invasive front (Kruger et al., 2015; Simonneau et al., 2018; Khou et al., 2020). Progressive infiltration of tumor-associated neutrophils (TANs) was observed during the evolution of benign papillomas to established SCC lesions in a chemical carcinogenesis model, and tumor escape mostly involved the impairment of anti-tumor CD8+ T cell responses mediated by high arginase activity, production of reactive oxygen species (ROS), nitrite (NO), and the induction of PD-1 expression on CD8+ T cells (Khou et al., 2020; Figure 1C). Similar to CAFs, TANs can also play an anti-tumoral effect in SCC. Challacombe et al. (2006) showed that neutrophil depletion increases SCC development, suggesting their role in mediating anti-tumor responses. In addition, neutrophils were necessary for the anti-tumoral effects of the Ingenol 3-angelate in experimental SCC (Challacombe et al., 2006). Such contradictory roles of these cells might be explained by the fact that, in the TME, tumor-derived factors can modulate their phenotype and function. TANs may acquire either an anti-tumor activity (N1 neutrophils), and/or a pro-tumoral activity (N2 neutrophils) mediated by TGF-b signaling (Fridlender et al., 2009; Figure 1C). In a mouse uterine cancer model, TANs exhibit N2 phenotype and promoted tumor growth through elastase release (Mahiddine et al., 2020). The authors also demonstrated that hypoxia is crucial for N2 phenotype maintenance and tumor oxygenation can revert TANs phenotype toward N1 (Mahiddine et al., 2020). Tumor-associated macrophages (TAMs) also represent a significant percentage of infiltrating phagocyte population in SCC (Kambayashi et al., 2013; Amôr et al., 2018; Simonneau et al., 2018; Jiang et al., 2019), and specific depletion of these cells inhibited tumor growth (Takahashi et al., 2009). The recruitment of monocytes into the SCC is mediated by CC chemokines such as CCL2 and, once in the TME, monocyte-derived macrophages are polarized toward a M1 or M2 phenotype (Pettersen et al., 2011; Caley et al., 2020). Due to the abundance of Th2-related cytokines such as IL-13, IL-4, and IL-10, the TME around SCC is often predominated by M2 macrophages (Linde et al., 2012b; Caley et al., 2020; Figure 1D). In addition to the TME cytokine profile, macrophages can also be M2-polarized through the secretion of tumor-derived exosomes. Exosomes derived from SCC promoted M2-like macrophage polarization through ERK1/2 signaling activation (Pang et al., 2020) besides promoting cell survival after ionizing radiation in vitro (Mutschelknaus et al., 2016; Figure 1D). Data from breast cancer also suggest that exosomes are capable of inducing IL-6 secretion, and a pro-survival phenotype in M2 macrophages, partially via gp130/STAT3 signaling (Ham et al., 2018). Interestingly, exosome-mediated communication in the TME works in both ways. Macrophage-derived exosomes increase cell migration and PD-L1 expression contributing to the establishment of an immunosuppressive TME (Bellmunt et al., 2019; Figure 1D). The contribution of TAMs directly to tumor growth occurs in early stages of carcinogenesis via malignant transformation and proliferation of epidermal cells. These cells also contribute to the progression of tumor by producing metalloproteinases (MMP) and increasing angiogenesis, thus facilitating the dissemination of tumor cells (Kerkelä et al., 2002; Linde et al.,2012a,b; Kambayashi et al., 2013; Figure 1D). TAMs can facilitate tumor escape by recruiting Tregs through the secretion of CXCL9/10/11 (ligands for CXCR3), CCL4 (ligands for CCR4/8), and CCL20 (ligands for CXCR3 and CCR6), which will further suppress local anti-tumoral immune responses (Ji et al., 2020; Figure 1D). Depletion of CCR2-expressing monocytes or macrophages with anti-CSF1R prevents the spontaneous development of SCC in transgenic mice (Antsiferova et al., 2017). Similarly, VEGFR-3 ligand blockade reduced SCC development by decreasing macrophage infiltration (Alitalo et al., 2013). Together, these findings strongly indicate the significant role of TAMs during SCC pathogenesis.
Given the importance of DCs in the skin, these cells are often thought to be the first immune cells to encounter tumor antigens from SCC (Valladeau and Saeland, 2005). SCC-derived DCs strongly induce CD4+ and CD8+ T-cell proliferation and IFN-γ production, thereby promoting the anti-tumoral response (Fujita et al., 2012). A significant decrease in DC infiltration has been reported in SCC and this is likely an important mechanism for tumor escape. By secreting TGF-β1, SCC inhibits DC migration and the ability of DC to mature into a potent T cell activator (Figure 1E; Halliday and Le, 2001; Weber et al., 2005). Further, in vitro stimulation of SCC-derived DCs showed an impaired ability of these cells to express costimulatory molecules when compared with DCs derived from normal skin, suggesting that SCC microenvironment display mechanisms that contribute to negative regulation in anti-tumor immune responses (Bluth et al., 2009). In SCC patients, this might be explained by the high expression of PD-L1 and PD-L2 in DCs (Jiao et al., 2017) or by the proximity of DCs to Tregs (Jang, 2008). Another myeloid cell that exerts a significant role in TME is the MDSCs, which promotes tumor progression by suppressing the effector function of anti-tumor immune cells from early to advanced stages of SCC (Figure 1E). Elevated circulating numbers of MDSCs were associated with high-grade SCC (Seddon et al., 2016). During early stages of tumor initiation in mice, Maalouf et al. (2012) reported an increased influx of MDSCs driven by the secretion of epidermal-derived CXCL5 and macrophage colony-stimulating factor (M-CSF) (Figure 1E). MDSCs were also found in advanced stages of SCC; these cells express high levels of CD200R+ that may interact with CD200+ tumor cells conferring immune privilege and favoring metastasis development (Stumpfova et al., 2010).
CD8+ T lymphocytes can directly eliminate tumor cells through the secretion of cytolytic enzymes, which are essential mediators of the anti-tumoral response (Nasti et al., 2015). However, SCC lesions display low frequencies of CD8+ T cells (Freeman et al., 2014) due, in part, to the presence of TGF-β, which inhibits CD8+ T cells infiltration and induces the expression of T cell exhaustion markers such as Tim-3, CTLA-4, and PD-1 (Weber et al., 2005; Linedale et al., 2017; Figure 1E). Blockade of PD-1 with monoclonal antibody was shown to increase tumor-infiltrating cytotoxic T lymphocytes (CTLs) resulting in anti-tumor activity against SCC growth (Belai et al., 2014), however, the depletion of CD8+ abrogated the efficacy of the anti-PD1 mAb treatment (Dodagatta-Marri et al., 2019), suggesting an association between the efficacy of PD-1 blockade therapies and the frequency of PD-1+ CD8+ T cells in the TME (Gros et al., 2014; Kansy et al., 2017; Kumagai et al., 2020).
Mice lacking CD4+ T cells and submitted to UVB-induced carcinogenesis displayed higher tumor growth associated with increased inflammation and increased number of p53+ tumor cells, demonstrating that this subset of T cells has an important role in controlling inflammation-associated carcinogenesis (Hatton et al., 2007). During skin carcinogenesis, CD4+ T cells are recruited via CXCL9- and CXCL10-mediated chemotaxis (Winkler et al., 2011). However, tumor cells can escape from T helper-mediated immune responses by polarizing CD4+ cells toward to a pro-tumor phenotype, characterized by Th2, Th17, and Treg cytokine profiles (Girardi et al., 2004; Zhang et al., 2013b; Figure 1F). IL-10-depleted mice are protected from UV-induced skin cancer due to their increased amounts of IFN-γ and enhanced numbers of CD4+ T cells, indicating a strong Th1-driven immune response (Loser et al., 2007). CD4+ T cells from a chemically-induced mouse model of SCC preferentially produced IL-4 and IL-10 (typical of Th2-type immunity) and these cells promote immunosuppression by inhibiting Th1 responses and recruiting Tregs (Yusuf et al., 2008; Nasti et al., 2011; Figure 1F). Th17 cells are recruited to the TME via CCL4 chemotaxis (Ortiz et al., 2015) and Wang et al. (2010) demonstrated that IL-17 contributes to skin tumorigenesis directly by increasing hyperproliferation of epithelial cells. Finally, IL-17 promoted the infiltration of myeloid cells, and decreased the infiltration of IFN-γ-producing CD8+ T lymphocytes contributing to the immunosuppressive niche during SCC (Wang et al., 2010; Figure 1F).
Evasion of the Immune Response: Potential Targets for Immunotherapies
As discussed above, an effective immune response is critical to control SCC development and progression (Burton et al., 2016). To efficiently eliminate SCC, leukocytes must infiltrate the TME, initiate cell-to-cell interactions so as to exert effective anti-tumoral functions (Halliday and Le, 2001; Weber et al., 2005; Ortner et al., 2017). T cell activation involves the engagement of receptors and co-receptors (Dustin and Shaw, 1999), but this activation is countered by a series of molecules called immune checkpoints that are responsible for controlling T cell function and induce self-tolerance (Yao et al., 2013; Waldman et al., 2020).
CTLA-4 and PD-1 are the most well-studied examples of T cell immune checkpoint molecules and tumor cells exploit these molecules to evade host immunity (Miao et al., 2019). Ipilimumab, an anti-CTLA-4 blocking monoclonal antibody, was the first immune checkpoint inhibitor to be tested and approved for the treatment of cancer (Phan et al., 2003). CTLA-4 is a transmembrane molecule that competes with the co-receptors B7-1 and B7-2 for CD28 binding and negatively regulates T cell activation (Brunet et al., 1987; Linsley et al., 1992; Figure 2A). During photocarcinogenesis, mice treated with anti-CTLA-4 developed significantly fewer tumors (Loser et al., 2005). Moreover, mice treated with anti-CTLA-4 developed long-lasting protective immunity, and in vitro CTLA-4 blockade inhibited the suppressor activity of UV-induced Tregs, suggesting that anti-CTLA-4-treated mice were protected from tumor growth due to the inhibition of Treg function in the TME (Loser et al., 2005; Figure 2A). Despite the beneficial effects of this therapy been observed in pre-clinical models of carcinogenesis, and in patients with melanoma (Hodi et al., 2010), there is presently only one ongoing (recruiting) clinical trial assessing the efficacy of ipilimumab in cutaneous SCC (NCT04620200).
FIGURE 2
T cell activation is also regulated by PD-1 and is mediated by the interaction with its ligands, PD-L1 and PD-L2 (Freeman et al., 2000; Latchman et al., 2001), both of which are highly expressed in SCC (Belai et al., 2014; Varki et al., 2018). Blocking PD-1 resulted in a potent anti-tumoral response in a chemically induced SCC model characterized by the infiltration of activated CD4+ and CD8+ T cells, IFN-γ levels, and reduced levels of the immunosuppressor cytokine TGF-β (Belai et al., 2014; Figure 2B). Currently, two FDA-approved immunotherapies for SCC (i.e., pembrolizumab and cemiplimab) target the interaction between PD-1/PD-L1 molecules. Despite reports of adverse events in this trial, approximately half the patients with advanced SCC responded to cemiplimab therapy (Migden et al., 2018). Immune checkpoints-based therapies are of great relevance especially for patients with advanced and metastatic disease that are not ideal candidates for surgical excision. A retrospective analysis showed that PD-1 inhibition produces durable responses among patients with advanced or metastatic SCC (In et al., 2020). In a multicenter study, the overall response rate obtained among patients with advanced SCC was even higher (Salzmann et al., 2020). In both studies, the dose used was well tolerated and the response rate satisfactory, therefore adding evidence and encouraging the implementation of immune checkpoint therapies for patients with advanced and unresectable SCC lesions.
Besides T cell exhaustion, SCC development is also associated with the generation of effector Tregs (Clark et al., 2008). Tregs are characterized by CD4, CD25, and transcription factor forkhead box P3 (FOXP3) expression and, once activated, these cells suppress exacerbated immune responses and maintain self-tolerance (Sakaguchi et al., 2010; Figure 2C). The depletion of CD25+ Tregs significantly reduced SCC development in mice (Ramos et al., 2012). Further, the presence of Tregs within the TME and the levels of PD-1 expression by Tregs directly correlate with immune evasion (Kumagai et al., 2020) and worse outcome (Azzimonti et al., 2015). Increased percentage of tumor-infiltrating Tregs was associated with loss of inflammasome activation, and SCC development in mice (Gasparoto et al., 2014). Tregs can be either locally differentiated by TGF-β (Chen et al., 2003) or recruited via the CCL4/CCL5-CCR5 axis (de Oliveira et al., 2017; Figure 2C). Tregs inhibitory function is mediated by IL-10 (Loser et al., 2007), and by the inhibition of CD4+ and CD8+ T cells proliferation and IFN-γ secretion (Lai et al., 2016; Figure 2C). Importantly, in mice, anti-TGF-β monotherapy was more efficient (approximately 20% of complete regression) than anti-PD-1 monotherapy (<3% of complete regression) and promoted long-term immunity against SCC (Dodagatta-Marri et al., 2019), therefore inhibition of Tregs recruitment or differentiation using antagonistic antibodies against CCR5 or neutralizing antibodies against TGF-β are relevant strategies for immunotherapy (Figure 2D). Moreover, although anti-PD-1 monotherapy elevates immunosuppressive Tregs in chemically induced SCC, 60% of complete regression in established tumors was achieved when combined with anti-TGF-β therapy, highlighting the benefits of combinatory immunotherapies for SCC (Dodagatta-Marri et al., 2019). It has recently been demonstrated that PD-1 blockade induces both recovery of dysfunctional PD-1+ CD8+ T cells and enhanced PD-1+ Treg cell-mediated immunosuppression (Kumagai et al., 2020). This study suggests that the balance of PD-1 expression between CD8+ effector T cells and Tregs in the TME should be considered as a clinically meaningful biomarker to predict the efficacy of PD-1-blocking immunotherapy in various cancers including SCC (Aksoylar and Boussiotis, 2020; Kumagai et al., 2020).
Another recently emerging area in cancer immunotherapy has focused on macrophages since these cells frequently infiltrate solid tumors, including SCC, and have a significant impact on prognosis (Takahara et al., 2009; Li, 2016; Figure 2E). Indeed, colony-stimulating factor 1 (CSF-1) is a key regulator of monocyte/macrophage recruitment and differentiation in the TME and promotes malignancy (Lin et al., 2001; Figure 2E). In a syngeneic mouse model of melanoma, pexidartinib, a potent inhibitor of the CSF-1 receptor (CSF-1R), conferred anti-tumoral response associated with TAMs reduction (Mok et al., 2014; Figure 2F). Pexidartinib is approved for the treatment of tenosynovial giant cell tumor (Lamb, 2019) and is currently being tested in several clinical trials, none of them for SCC but with great potential (Benner et al., 2020). CCL2, also known as MCP-1, is another monocyte chemoattractant that promotes carcinogenesis by recruiting TAMs and inducing immune evasion through PD-1 signaling (Yang et al., 2020; Figure 2E). A phase II trial of trabectedin, a small molecule that specifically inhibits CCL2 synthesis, showed effectiveness as a single agent in platinum-sensitive patients with advanced recurrent ovarian cancer (Krasner et al., 2007; Figure 2F). Although trabectedin has been used to treat ovarian and breast cancer as well as soft tissue sarcomas (D’Incalci and Zambelli, 2016), its effect against SCC has yet to be investigated. While inhibition of macrophage recruitment might seem promising, M1-polarized macrophages exert potent anti-tumoral immune responses. Accordingly, M1-polarization of TAMs reversed the immunosuppressive state of TAMs and promoted tumor regression in models of ovarian cancer, melanoma, and glioblastoma (Zhang et al., 2019; Figure 2F). However, macrophage-based therapies remain highly challenging due to the plasticity of these cells (i.e., M1 macrophages can easily switch for M2 phenotype upon stimulus) (Linde et al., 2012a). To overcome this, sustained M1 differentiation is required and nanoparticles containing IL-12 promote macrophage conversion from the M2 to the M1 phenotype in the TME. Notably, this strategy has protected mice from melanoma development (Wang et al., 2017; Figure 2F). Shields et al. (2020) also successfully demonstrated that sustaining the M1 phenotype in the TME effectively controlled melanoma progression. Interestingly, this research team developed discoidal particles called “backpacks” that attach to macrophages and constantly deliver IFN-γ to sustain the M1 phenotype (Shields et al., 2020; Figure 2F).
Lastly, but still of considerable importance, soluble components of the TME, such as cytokines, chemokines, and growth factors exert a critical role during tumorigenesis (Dranoff, 2004). For example, IL-33 is abundantly expressed in epithelial cells and several other cell types (Hammad and Lambrecht, 2015), and as such it appears to be a great target for cutaneous SCC therapy. Due to its central role in mediating type 2 innate and adaptive immunity via the ST2 receptor, IL-33 has been extensively studied in cancer and inflammatory diseases (Liew et al., 2016). In mice, IL-33 promotes SCC development by increasing M2 macrophage infiltration and decreasing NK cell cytotoxicity (Amôr et al., 2018; Figure 2G). IL-33 promotes differentiation of macrophages that in turn, send paracrine TGF-β signals to tumor cells consequently inducing invasive behavior (Taniguchi et al., 2020; Figure 2G). In addition, IL-33 can acts directly on tumor cells to enhance chemoresistance (Fang et al., 2017), highlighting that IL-33/ST2 targeting should be considered further for SCC therapies (Figure 2G). One possible way to disrupt the IL-33/ST2 signaling is via the soluble form of the IL-33 receptor, sST2, which acts as a decoy receptor and prevents the binding of IL-33 to ST2L on the cell surface (Hayakawa et al., 2007; Griesenauer and Paczesny, 2017; Figure 2H). Although the effects of sST2 administration have not been tested in SCC, its potential therapeutic benefits were demonstrated in colorectal carcinoma (Akimoto et al., 2016). The reduced tumor growth observed in sST2-treated mice was associated with decreased angiogenesis, and inhibition of macrophage infiltration and M2 polarization (Akimoto et al., 2016; Figure 2H).
Concluding Remarks and Perspectives
Growing evidence highlights the crucial contribution of immune and non-immune cells during SCC pathogenesis, most notably in the TME, and the targeting of this supportive tumor niche is an important part of emerging therapies in this cancer. As the understanding of the mechanistic events that permit tumor evasion from immunosurveillance emerges, comprehensive treatment methods that enhance anti-tumor immunity and the sensitivity of tumor cells to chemotherapies will revolutionize the therapy landscape in SCC. Although emerged as the advent for cancer treatment, one of the major limitations of immunotherapy is the development of acquired resistance to treatment due to triggering of compensatory mechanisms resulting in tumor relapse/progression. For example, in SCC, the anti-PD-1 treatment that is supposed to reduce T cell suppression also promotes the infiltration of Tregs, which are known to directly assist tumor escape in experimental SCC (Dodagatta-Marri et al., 2019). Similarly, in head and neck SCC (HNSCC), PD-1 blockade culminated in Tim-3 upregulation, supporting a circuit of compensatory suppressor signaling allowing tumor escape (Shayan et al., 2017). Therefore, combinatory therapies are the more promising future strategies in SCC therapy. Clinical data have shown that melanoma patients treated with anti-PD-1 and anti-CTLA-4 monoclonal antibodies (mAb) presented tumor reduction (Wolchok et al., 2013; Postow et al., 2015). Similarly, simultaneous blockade of GITR and PD-L1 demonstrated safety and efficacy against advanced solid tumors (Heinhuis et al., 2019). Results from over 50% of patients with recurrent or metastatic HNSCC have shown disease stabilization after treatment with motolimod, an agonist of TLR8 which stimulates NK, DC, and monocytes, in combination with cetuximab in a phase Ib clinical trial (Chow et al., 2017). Altogether, these studies represent an exciting new horizon that could be also tested for cutaneous SCC treatment.
Additionally, the next-generation sequencing (NGS) technology has emerged as one of the most powerful tools for cancer research since enables efficient and accurate detection of somatic mutations frequently associated with treatment resistance (Łuksza et al., 2017). Using the NGS approach, Lobl et al. (2020) identified the co-occurrence of ERBB4 and STK11 mutations in localized cutaneous SCC, which prompted the researchers to suggest a new therapeutic approach by inhibiting CDH1 and the Wnt pathway. Besides identification of tumor mutational burden, NGS also allows the prediction of response and development of a personalized treatment that might significantly improve outcomes for cancer patients (Holbrook et al., 2011; Roychowdhury et al., 2011; Chen et al., 2019). Based on that, NGS could and should be incorporated to assess mutations not only in tumor cells but also in immune cells of SCC patients that will help to overcome the differences of response rate observed among patients with similar malignancy and treatment, leading to the development of personalized therapies improving clinical outcomes.
Herein, we provide a range of alternative targets focused on the regulation of immune cells beyond T cells to promote anti-tumoral responses. However, a reasonable amount of the work regarding immunological therapeutic strategies remains to be evaluated against SCC, highlighting opportunities for therapeutic intervention. Since the composition of the TME is heterogeneous and result in different TME subclasses not only among patients or tumor types but also within a patient’s tumor, it is important to consider the differences in the spatial localization, density, and functional orientation of immune cells in the TME, in order to predict and improve the clinical benefits [reviewed extensively by Pérez-Ruiz et al. (2020)]. Most exciting to us are experimental strategies around macrophage- and/or IL-33-based therapies in SCC. We concede that most of the data regarding these strategies are derived from experimental models with little clinical insight, but animal models do provide key early insights into the role of immune cells and soluble factors in SCC tumorigenesis. We contend that these limitations will be lessened as further translational investigations using human subjects and clinical trials are implemented to better assess the efficacy of alternative strategies for SCC immunotherapy.
Statements
Author contributions
NA contributed to graphic drawing and drafting of the manuscript. PS contributed to drafting of the manuscript. AC contributed to concept generation and drafting of the manuscript. All authors contributed to the article and approved the submitted version.
Funding
The work was supported by grants #2014/06215-1, #2018/10529-2, and#2021/00217-6 São Paulo Research Foundation (FAPESP) and by CNPq(#302578/2019-6). This study was also financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brazil (CAPES) – Finance Code 001.
Acknowledgments
The authors would like to thank Blooming LLC, scientific consulting and editing, for the proofreading and revision of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AkimotoM.MaruyamaR.TakamaruH.OchiyaT.TakenagaK. (2016). Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment.Nat. Commun.7:13589. 10.1038/ncomms13589
2
AksoylarH. I.BoussiotisV. A. (2020). PD-1(+) T(reg) cells: a foe in cancer immunotherapy?Nat. Immunol.211311–1312. 10.1038/s41590-020-0801-7
3
AlitaloA. K.ProulxS. T.KaramanS.AebischerD.MartinoS.JostM.et al (2013). VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.Cancer Res.734212–4221. 10.1158/0008-5472.can-12-4539
4
AmôrN. G.de OliveiraC. E.GasparotoT. H.BoasV. G. V.PerriG.KanenoR.et al (2018). ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate.Oncotarget9:25768. 10.18632/oncotarget.25768
5
AntsiferovaM.Piwko-CzuchraA.CangkramaM.WietechaM.SahinD.BirknerK.et al (2017). Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages.EMBO Mol. Med.927–45. 10.15252/emmm.201606493
6
AsgariM. M.RayG. T.QuesenberryC. P.Jr.KatzK. A.SilverbergM. J. (2017). Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection.CD4 Count. Viral Load. JAMA Dermatol.153892–896. 10.1001/jamadermatol.2017.1716
7
AzzimontiB.ZavattaroE.ProvasiM.VidaliM.ConcaA.CatalanoE.et al (2015). Intense Foxp3+ CD25+ regulatory T-cell infiltration is associated with high-grade cutaneous squamous cell carcinoma and counterbalanced by CD8+/Foxp3+ CD25+ ratio.Br. J. Dermatol.17264–73. 10.1111/bjd.13172
8
BelaiE. B.de OliveiraC. E.GasparotoT. H.RamosR. N.TorresS. A.GarletG. P.et al (2014). PD-1 blockage delays murine squamous cell carcinoma development.Carcinogenesis35424–431. 10.1093/carcin/bgt305
9
BelkinD. A.MitsuiH.WangC. Q.GonzalezJ.ZhangS.ShahK. R.et al (2013). CD200 upregulation in vascular endothelium surrounding cutaneous squamous cell carcinoma.JAMA Dermatol.149178–186. 10.1001/jamadermatol.2013.1609
10
BellmuntÀM.López-PuertoL.LorenteJ.ClosaD. (2019). Involvement of extracellular vesicles in the macrophage-tumor cell communication in head and neck squamous cell carcinoma.PLoS One14:e0224710. 10.1371/journal.pone.0224710
11
BennerB.GoodL.QuirogaD.SchultzT. E.KassemM.CarsonW. E.et al (2020). Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.Drug Des. Devel. Ther.141693–1704. 10.2147/dddt.s253232
12
BluthM. J.ZabaL. C.MoussaiD.Suárez-FariñasM.KaporisH.FanL.et al (2009). Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation.J. Invest. Dermatol.1292451–2462. 10.1038/jid.2009.96
13
BrunetJ. F.DenizotF.LucianiM. F.Roux-DossetoM.SuzanM.MatteiM. G.et al (1987). A new member of the immunoglobulin superfamily–CTLA-4.Nature328267–270. 10.1038/328267a0
14
BurtonK. A.AshackK. A.KhachemouneA. (2016). Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease.Am. J. Clin. Dermatol.17491–508. 10.1007/s40257-016-0207-3
15
CaleyM. P.MartinsV. L.MooreK.LashariM.NissinenL.KähäriV. M.et al (2020). Loss of Laminin α3 induces cell invasion and macrophage infiltration in cutaneous squamous cell carcinoma.Br. J. Dermatol.2020:19571. 10.1111/bjd.19471
16
ChallacombeJ. M.SuhrbierA.ParsonsP. G.JonesB.HampsonP.KavanaghD.et al (2006). Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate.J. Immunol.1778123–8132. 10.4049/jimmunol.177.11.8123
17
ChenW.JinW.HardegenN.LeiK. J.LiL.MarinosN.et al (2003). Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.J. Exp. Med.1981875–1886. 10.1084/jem.20030152
18
ChenX.SongE. (2019). Turning foes to friends: targeting cancer-associated fibroblasts.Nat. Rev. Drug Dis.1899–115. 10.1038/s41573-018-0004-1
19
ChenY.LiuQ.ChenZ.WangY.YangW.HuY.et al (2019). PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.J. Exp. Clin. Cancer Res. CR38:193. 10.1186/s13046-019-1192-1
20
ChowL. Q. M.MorishimaC.EatonK. D.BaikC. S.GoulartB. H.AndersonL. N.et al (2017). Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.Clin. Cancer Res.232442–2450. 10.1158/1078-0432.CCR-16-1934
21
ClarkR. A.HuangS. J.MurphyG. F.MolletI. G.HijnenD.MuthukuruM.et al (2008). Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells.J. Exp. Med.2052221–2234. 10.1084/jem.20071190
22
de OliveiraC. E.GasparotoT. H.PinheiroC. R.AmôrN. G.NogueiraM. R. S.KanenoR.et al (2017). CCR5-dependent homing of T regulatory cells to the tumor microenvironment contributes to skin squamous cell carcinoma development.Mole. Cancer Ther.1617–0341. 10.1158/1535-7163.MCT-17-0341
23
D’IncalciM.ZambelliA. (2016). Trabectedin for the treatment of breast cancer.Exp. Opin. Investig. Drugs25105–115. 10.1517/13543784.2016.1124086
24
Dodagatta-MarriE.MeyerD. S.ReevesM. Q.PaniaguaR.ToM. D.BinnewiesM.et al (2019). α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.J. Immunother. Cancer7:62. 10.1186/s40425-018-0493-9
25
DranoffG. (2004). Cytokines in cancer pathogenesis and cancer therapy.Nat. Rev. Cancer411–22. 10.1038/nrc1252
26
DuanH.KogaT.MasudaT.MashinoT.ImafukuS.TeraoH.et al (2000). CD1a+, CD3+, CD4+, CD8+, CD68+ and cutaneous lymphocyte-associated antigen-positive cells in Bowen’s disease.Br. J. Dermatol.1431211–1216. 10.1046/j.1365-2133.2000.03890.x
27
DustinM. L.ShawA. S. (1999). Costimulation: building an immunological synapse.Science283649–650. 10.1126/science.283.5402.649
28
EuvrardS.KanitakisJ.ClaudyA. (2003). Skin cancers after organ transplantation.N Engl J Med3481681–1691. 10.1056/NEJMra022137
29
FangM.LiY.HuangK.QiS.ZhangJ.ZgodzinskiW.et al (2017). IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment.Cancer Res.772735–2745. 10.1158/0008-5472.CAN-16-1602
30
FlorenceM. E.MassudaJ. Y.BröckerE. B.MetzeK.CintraM. L.SouzaE. M. (2011). Angiogenesis in the progression of cutaneous squamous cell carcinoma: an immunohistochemical study of endothelial markers.Clinics66465–468. 10.1590/s1807-59322011000300018
31
FreemanA.BridgeJ. A.MaruthayanarP.OvergaardN. H.JungJ. W.SimpsonF.et al (2014). Comparative immune phenotypic analysis of cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in immune-competent individuals: proportional representation of CD8+ T-cells but not FoxP3+ Regulatory T-cells is associated with disease stage.PLoS One9:e110928. 10.1371/journal.pone.0110928
32
FreemanG. J.LongA. J.IwaiY.BourqueK.ChernovaT.NishimuraH.et al (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.J. Exp. Med.1921027–1034. 10.1084/jem.192.7.1027
33
FridlenderZ. G.SunJ.KimS.KapoorV.ChengG.LingL.et al (2009). Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN.Cancer Cell16183–194. 10.1016/j.ccr.2009.06.017
34
FujitaH.Suárez-FariñasM.MitsuiH.GonzalezJ.BluthM. J.ZhangS.et al (2012). Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity.J. Invest. Dermatol.1321645–1655. 10.1038/jid.2012.34
35
GambichlerT.GnielkaM.RüddelI.StockflethE.StückerM.SchmitzL. (2017). Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.Cancer Immunol. Immunother.661199–1204. 10.1007/s00262-017-2015-x
36
GasparotoT. H.de OliveiraC. E.de FreitasL. T.PinheiroC. R.HoriJ. I.GarletG. P.et al (2014). Inflammasome activation is critical to the protective immune response during chemically induced squamous cell carcinoma.PLoS One9:e107170. 10.1371/journal.pone.0107170
37
GirardiM.OppenheimD.GlusacE. J.FillerR.BalmainA.TigelaarR. E.et al (2004). Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma.J. Invest. Dermatol.122699–706. 10.1111/j.0022-202X.2004.22342.x
38
GriesenauerB.PaczesnyS. (2017). The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases.Front. Immunol.8:475. 10.3389/fimmu.2017.00475
39
GrosA.RobbinsP. F.YaoX.LiY. F.TurcotteS.TranE.et al (2014). PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors.J. Clin. Investig.1242246–2259. 10.1172/JCI73639
40
HallidayG. M.LeS. (2001). Transforming growth factor-beta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances.Langerhans Cell Migrat. Skin. Int. Immunol.131147–1154. 10.1093/intimm/13.9.1147
41
HamS.LimaL. G.ChaiE. P. Z.MullerA.LobbR. J.KrumeichS.et al (2018). Breast Cancer-Derived Exosomes Alter Macrophage Polarization via gp130/STAT3 Signaling.Front. Immunol.9:871. 10.3389/fimmu.2018.00871
42
HammadH.LambrechtB. N. (2015). Barrier Epithelial Cells and the Control of Type 2 Immunity.Immunity4329–40. 10.1016/j.immuni.2015.07.007
43
HattonJ. L.ParentA.ToberK. L.HoppesT.WulffB. C.DuncanF. J.et al (2007). Depletion of CD4+ cells exacerbates the cutaneous response to acute and chronic UVB exposure.J. Invest. Dermatol.1271507–1515. 10.1038/sj.jid.5700746
44
HayakawaH.HayakawaM.KumeA.TominagaS. (2007). Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation.J. Biol. Chem.28226369–26380. 10.1074/jbc.M704916200
45
HeinhuisK. M.CarlinoM.JoergerM.di NicolaM.MeniawyT.RotteyS.et al (2019). Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clini.JAMA Oncology61–8. 10.1001/jamaoncol.2019.3848
46
HodiF. S.O’DayS. J.McDermottD. F.WeberR. W.SosmanJ. A.HaanenJ. B.et al (2010). Improved survival with ipilimumab in patients with metastatic melanoma.N. Engl. J. Med.363711–723. 10.1056/NEJMoa1003466
47
HolbrookJ. D.ParkerJ. S.GallagherK. T.HalseyW. S.HughesA. M.WeigmanV. J.et al (2011). Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine.J. Translat. Med.9:119. 10.1186/1479-5876-9-119
48
InG. K.VaidyaP.FilkinsA.HermelD. J.KingK. G.RagabO.et al (2020). PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.J. Cancer Res. Clin. Oncol.20203458–3456. 10.1007/s00432-020-03458-6
49
JangT. J. (2008). Prevalence of Foxp3 positive T regulatory cells is increased during progression of cutaneous squamous tumors.Yonsei Med. J.49942–948. 10.3349/ymj.2008.49.6.942
50
JiA. L.RubinA. J.ThraneK.JiangS.ReynoldsD. L.MeyersR. M.et al (2020). Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma.Cell182497.e–514.e. 10.1016/j.cell.2020.05.039
51
JiangX.WangM.CyrusN.YanezD. A.LacherR. K.RhebergenA. M.et al (2019). Human keratinocyte carcinomas have distinct differences in their tumor-associated macrophages.Heliyon5:e02273. 10.1016/j.heliyon.2019.e02273
52
JiaoQ.LiuC.LiW.FangF.QianQ.ZhangX. (2017). Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.Clin. Exp. Immunol.188420–429. 10.1111/cei.12921
53
KambayashiY.FujimuraT.AibaS. (2013). Comparison of immunosuppressive and immunomodulatory cells in keratoacanthoma and cutaneous squamous cell carcinoma.Acta Derm Venereol.93663–668. 10.2340/00015555-1597
54
KansyB. A.Concha-BenaventeF.SrivastavaR. M.JieH.-B.ShayanG.LeiY.et al (2017). PD-1 Status in CD8(+) T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.Cancer Res.776353–6364. 10.1158/0008-5472.CAN-16-3167
55
KerkeläE.Ala-ahoR.KlemiP.GrénmanS.ShapiroS. D.KähäriV. M.et al (2002). Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome.J. Pathol.198258–269. 10.1002/path.1198
56
KhouS.PopaA.LuciC.BihlF.Meghraoui-KheddarA.BourdelyP.et al (2020). Tumor-Associated Neutrophils Dampen Adaptive Immunity and Promote Cutaneous Squamous Cell Carcinoma Development.Cancers12:12071860. 10.3390/cancers12071860
57
KrasnerC. N.McMeekinD. S.ChanS.BralyP. S.RenshawF. G.KayeS.et al (2007). A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.Br. J. Cancer971618–1624. 10.1038/sj.bjc.6604088
58
KrugerP.SaffarzadehM.WeberA. N.RieberN.RadsakM.von BernuthH.et al (2015). Neutrophils: Between host defence, immune modulation, and tissue injury.PLoS Pathog.11:e1004651. 10.1371/journal.ppat.1004651
59
KumagaiS.TogashiY.KamadaT.SugiyamaE.NishinakamuraH.TakeuchiY.et al (2020). The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.Nat. Immunol.211346–1358. 10.1038/s41590-020-0769-3
60
LaiC.AugustS.AlbibasA.BeharR.ChoS. Y.PolakM. E.et al (2016). OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.Clin. Cancer Res.224236–4248. 10.1158/1078-0432.ccr-15-2614
61
LambY. N. (2019). Pexidartinib: First Approval.Drugs791805–1812. 10.1007/s40265-019-01210-0
62
LatchmanY.WoodC. R.ChernovaT.ChaudharyD.BordeM.ChernovaI.et al (2001). PD-L2 is a second ligand for PD-1 and inhibits T cell activation.Nat Immunol.2261–268. 10.1038/85330
63
LiX. (2016). TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma.Tumour Biol.375585–5590. 10.1007/s13277-015-4388-9
64
LiewF. Y.GirardJ.-P.TurnquistH. R. (2016). Interleukin-33 in health and disease.Nat. Rev. Immunol.16676–689. 10.1038/nri.2016.95
65
LinE. Y.NguyenA. V.RussellR. G.PollardJ. W. (2001). Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.J. Exp. Med.193727–740. 10.1084/jem.193.6.727
66
LindeN.GutschalkC. M.HoffmannC.YilmazD.MuellerM. M. (2012a). Integrating macrophages into organotypic co-cultures: a 3D in vitro model to study tumor-associated macrophages.PLoS One7:e40058. 10.1371/journal.pone.0040058
67
LindeN.LederleW.DepnerS.van RooijenN.GutschalkC. M.MuellerM. M. (2012b). Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages.J. Pathol.22717–28. 10.1002/path.3989
68
LinedaleR.SchmidtC.KingB. T.GankoA. G.SimpsonF.PanizzaB. J.et al (2017). Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.PLoS One12:e0175755. 10.1371/journal.pone.0175755
69
LinsleyP. S.GreeneJ. L.TanP.BradshawJ.LedbetterJ. A.AnasettiC.et al (1992). Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.J. Exp. Med.1761595–1604. 10.1084/jem.176.6.1595
70
LoblM. B.ClareyD.HigginsS.SuttonA.HansenL.WysongA. (2020). Targeted next-generation sequencing of matched localized and metastatic primary high-risk SCCs identifies driver and co-occurring mutations and novel therapeutic targets.J. Dermatol. Sci.9930–43. 10.1016/j.jdermsci.2020.05.007
71
LoserK.ApeltJ.VoskortM.MohauptM.BalkowS.SchwarzT.et al (2007). IL-10 controls ultraviolet-induced carcinogenesis in mice.J. Immunol.179365–371. 10.4049/jimmunol.179.1.365
72
LoserK.SchererA.KrummenM. B.VargaG.HiguchiT.SchwarzT.et al (2005). An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice.J. Immunol.1745298–5305. 10.4049/jimmunol.174.9.5298
73
ŁukszaM.RiazN.MakarovV.BalachandranV. P.HellmannM. D.SolovyovA.et al (2017). A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.Nature551517–520. 10.1038/nature24473
74
MaaloufS. W.TheivakumarS.OwensD. M. (2012). Epidermal α6β4 integrin stimulates the influx of immunosuppressive cells during skin tumor promotion.J. Dermatol. Sci.66108–118. 10.1016/j.jdermsci.2012.02.009
75
MahiddineK.BlaisdellA.MaS.Créquer-GrandhommeA.LowellC. A.ErlebacherA. (2020). Relief of tumor hypoxia unleashes the tumoricidal potential of neutrophils.J. Clin. Investig.130389–403. 10.1172/JCI130952
76
MiaoY.YangH.LevorseJ.YuanS.PolakL.SribourM.et al (2019). Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells.Cell1771172.e–1186.e. 10.1016/j.cell.2019.03.025
77
MigdenM. R.RischinD.SchmultsC. D.GuminskiA.HauschildA.LewisK. D.et al (2018). PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.N. Engl. J. Med.379341–351. 10.1056/NEJMoa1805131
78
MokS.KoyaR. C.TsuiC.XuJ.RobertL.WuL.et al (2014). Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.Cancer Res.74153–161. 10.1158/0008-5472.can-13-1816
79
MoussaiD.MitsuiH.PettersenJ. S.PiersonK. C.ShahK. R.Suárez-FariñasM.et al (2011). The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C.J. Invest. Dermatol.131229–236. 10.1038/jid.2010.266
80
MutschelknausL.PetersC.WinklerK.YentrapalliR.HeiderT.AtkinsonM. J.et al (2016). Exosomes Derived from Squamous Head and Neck Cancer Promote Cell Survival after Ionizing Radiation.PLoS One11:e0152213. 10.1371/journal.pone.0152213
81
NastiT. H.IqbalO.TamimiI. A.GeiseJ. T.KatiyarS. K.YusufN. (2011). Differential roles of T-cell subsets in regulation of ultraviolet radiation induced cutaneous photocarcinogenesis.Photochem. Photobiol.87387–398. 10.1111/j.1751-1097.2010.00859.x
82
NastiT. H.RudemillerK. J.CochranJ. B.KimH. K.TsurutaY.FinebergN. S.et al (2015). Immunoprevention of chemical carcinogenesis through early recognition of oncogene mutations.J. Immunol.1942683–2695. 10.4049/jimmunol.1402125
83
ÖhlundD.ElyadaE.TuvesonD. (2014). Fibroblast heterogeneity in the cancer wound.J. Exp. Med.2111503–1523. 10.1084/jem.20140692
84
OmlandS. H.AhlströmM. G.GerstoftJ.PedersenG.MoheyR.PedersenC.et al (2018). Risk of skin cancer in patients with HIV: A Danish nationwide cohort study.J. Am. Acad. Dermatol.79689–695. 10.1016/j.jaad.2018.03.024
85
OrtizM. L.KumarV.MartnerA.MonyS.DonthireddyL.CondamineT.et al (2015). Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells.J. Exp. Med.212351–367. 10.1084/jem.20140835
86
OrtnerD.TrippC. H.KomendaK.DubracS.ZelgerB.HermannM.et al (2017). Langerhans cells and NK cells cooperate in the inhibition of chemical skin carcinogenesis.Oncoimmunology6:e1260215. 10.1080/2162402x.2016.1260215
87
PangX.WangS.-S.ZhangM.JiangJ.FanH.-Y.WuJ.-S.et al (2020). OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.Cancer Immunol. Immunother.20202741–2742. 10.1007/s00262-020-02741-2
88
Pérez-RuizE.MeleroI.KopeckaJ.Sarmento-RibeiroA. B.García-ArandaM.de Las RivasJ. (2020). Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.Drug Resist. Updates53:100718. 10.1016/j.drup.2020.100718
89
PettersenJ. S.Fuentes-DuculanJ.Suárez-FariñasM.PiersonK. C.Pitts-KieferA.FanL.et al (2011). Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated.J. Invest. Dermatol.1311322–1330. 10.103/jid.2011.9
90
PhanG. Q.YangJ. C.SherryR. M.HwuP.TopalianS. L.SchwartzentruberD. J.et al (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.Proc. Natl. Acad. Sci. U S A1008372–8377. 10.1073/pnas.1533209100
91
PostowM. A.ChesneyJ.PavlickA. C.RobertC.GrossmannK.McDermottD.et al (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N. England J. Med.3722006–2017. 10.1056/NEJMoa1414428
92
QueS. K. T.ZwaldF. O.SchmultsC. D. (2018a). Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging.J. Am. Acad. Dermatol.78237–247. 10.1016/j.jaad.2017.08.059
93
QueS. K. T.ZwaldF. O.SchmultsC. D. (2018b). Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.J. Am. Acad. Dermatol.78249–261. 10.1016/j.jaad.2017.08.058
94
RamosR. N.OliveiraC. E.GasparotoT. H.MalaspinaT. S. S.BelaiE. B.CavassaniK. A.et al (2012). Cd25+ T cell depletion impairs murine squamous cell carcinoma development via modulation of antitumor immune responses.Carcinogenesis33:103. 10.1093/carcin/bgs103
95
RoychowdhuryS.IyerM. K.RobinsonD. R.LonigroR. J.WuY.-M.CaoX.et al (2011). Personalized oncology through integrative high-throughput sequencing: a pilot study.Sci. Translat. Med.3:111ra121. 10.1126/scitranslmed.3003161
96
SakaguchiS.MiyaraM.CostantinoC. M.HaflerD. A. (2010). FOXP3+ regulatory T cells in the human immune system.Nat. Rev. Immunol.10490–500. 10.1038/nri2785
97
SalzmannM.LeiterU.LoquaiC.ZimmerL.UgurelS.GutzmerR.et al (2020). Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.Eur. J. Cancer138125–132. 10.1016/j.ejca.2020.07.029
98
SeddonA.HockB.MillerA.FreiL.PearsonJ.McKenzieJ.et al (2016). Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells.J. Dermatol. Sci.83124–130. 10.1016/j.jdermsci.2016.04.013
99
ShayanG.SrivastavaR.LiJ.SchmittN.KaneL. P.FerrisR. L. (2017). Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.Oncoimmunology6:e1261779. 10.1080/2162402X.2016.1261779
100
ShieldsC. W.EvansM. A.WangL. L.BaughN.IyerS.WuD.et al (2020). Cellular backpacks for macrophage immunotherapy.Sci. Adv.6:eaaz6579. 10.1126/sciadv.aaz6579
101
SiljamäkiE.RappuP.RiihiläP.NissinenL.KähäriV. M.HeinoJ. (2020). H-Ras activation and fibroblast-induced TGF-β signaling promote laminin-332 accumulation and invasion in cutaneous squamous cell carcinoma.Matrix Biol.8726–47. 10.1016/j.matbio.2019.09.001
102
SimonneauM.FrouinE.HuguierV.JermidiC.JégouJ. F.GodetJ.et al (2018). Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression.Oncotarget936457–36473. 10.18632/oncotarget.26355
103
StangA.KhilL.KajüterH.PandeyaN.SchmultsC. D.RuizE. S.et al (2019). Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents.J. Eur. Acad. Dermatol. Venereol. JEADV33(Suppl. 8), 6–10. 10.1111/jdv.15967
104
StumpfovaM.RatnerD.DesciakE. B.EliezriY. D.OwensD. M. (2010). The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma.Cancer Res.702962–2972. 10.1158/0008-5472.can-09-4380
105
TakaharaM.ChenS.KidoM.TakeuchiS.UchiH.TuY.et al (2009). Stromal CD10 expression, as well as increased dermal macrophages and decreased Langerhans cells, are associated with malignant transformation of keratinocytes.J. Cutan Pathol.36668–674. 10.1111/j.1600-0560.2008.01139.x
106
TakahashiT.IbataM.YuZ.ShikamaY.EndoY.MiyauchiY.et al (2009). Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b(+)/CCR3(-)/Gr-1(-) cells cytotoxic again.Cancer Immunol. Immunother.582011–2023. 10.1007/s00262-009-0708-5
107
TaniguchiS.ElhanceA.van DuzerA.KumarS.LeitenbergerJ. J.OshimoriN. (2020). Tumor-initiating cells establish an IL-33-TGF-β niche signaling loop to promote cancer progression.Science369aay1813. 10.1126/science.aay1813
108
ThomsonP. J. (2018). Perspectives on oral squamous cell carcinoma prevention-proliferation, position, progression and prediction.J. Oral Pathol. Med.47803–807. 10.1111/jop.12733
109
ToniniT.RossiF.ClaudioP. P. (2003). Molecular basis of angiogenesis and cancer.Oncogene226549–6556. 10.1038/sj.onc.1206816
110
TrompD. M.BrouhaX. D. R.HordijkG.-J.WinnubstJ. A. M.de LeeuwJ. R. J. (2005). Patient factors associated with delay in primary care among patients with head and neck carcinoma: a case-series analysis.Family Pract.22554–559. 10.1093/fampra/cmi058
111
ValladeauJ.SaelandS. (2005). Cutaneous dendritic cells.Semin Immunol.17273–283. 10.1016/j.smim.2005.05.009
112
VarkiV.IoffeO. B.BentzenS. M.HeathJ.CelliniA.FelicianoJ.et al (2018). PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.Cancer Immunol. Immunother.67805–814. 10.1007/s00262-018-2138-8
113
WaldmanA. D.FritzJ. M.LenardoM. J. (2020). A guide to cancer immunotherapy: from T cell basic science to clinical practice.Nat. Rev. Immunol.20201–18. 10.1038/s41577-020-0306-5
114
WangL.YiT.ZhangW.PardollD. M.YuH. (2010). IL-17 enhances tumor development in carcinogen-induced skin cancer.Cancer Res.7010112–10120. 10.1158/0008-5472.can-10-0775
115
WangY.LinY. X.QiaoS. L.AnH. W.MaY.QiaoZ. Y.et al (2017). Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment.Biomaterials112153–163. 10.1016/j.biomaterials.2016.09.034
116
WeberF.ByrneS. N.LeS.BrownD. A.BreitS. N.ScolyerR. A.et al (2005). Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system.Cancer Immunol. Immunother.54898–906. 10.1007/s00262-004-0652-3
117
WelshM. M.ApplebaumK. M.SpencerS. K.PerryA. E.KaragasM. R.NelsonH. H. (2009). CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer.Cancer Res.696158–6163. 10.1158/0008-5472.can-09-0415
118
WinklerA. E.BrotmanJ. J.PittmanM. E.JuddN. P.LewisJ. S.Jr.SchreiberR. D.et al (2011). CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis.Cancer Res.715707–5716. 10.1158/0008-5472.can-11-0907
119
WolchokJ. D.KlugerH.CallahanM. K.PostowM. A.RizviN. A.LesokhinA. M.et al (2013). Nivolumab plus ipilimumab in advanced melanoma.N. England J. Med.369122–133. 10.1056/NEJMoa1302369
120
YangH.ZhangQ.XuM.WangL.ChenX.FengY.et al (2020). CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.Mol. Cancer19:41. 10.1186/s12943-020-01165-x
121
YaoS.ZhuY.ChenL. (2013). Advances in targeting cell surface signalling molecules for immune modulation.Nat. Rev. Drug Discov.12130–146. 10.1038/nrd3877
122
YusufN.NastiT. H.KatiyarS. K.JacobsM. K.SeibertM. D.GinsburgA. C.et al (2008). Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis.Cancer Res.683924–3930. 10.1158/0008-5472.can-07-3059
123
ZhangF.ParayathN. N.EneC. I.StephanS. B.KoehneA. L.CoonM. E.et al (2019). Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers.Nat. Commun.10:3974. 10.1038/s41467-019-11911-5
124
ZhangJ.ChenL.LiuX.KammertoensT.BlankensteinT.QinZ. (2013a). Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens.Cancer Res.732770–2781. 10.1158/0008-5472.CAN-12-3022
125
ZhangJ.ChenL.XiaoM.WangC.QinZ. (2011). FSP1+ fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation.Am. J. Pathol.178382–390. 10.1016/j.ajpath.2010.11.017
126
ZhangS.FujitaH.MitsuiH.YanofskyV. R.Fuentes-DuculanJ.PettersenJ. S.et al (2013b). Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma.PLoS One8:e62154. 10.1371/journal.pone.0062154
Summary
Keywords
cutaneous squamous cell carcinoma, immunotherapy, tumor microenvironment, checkpoint inhibitors, regulatory T cell, macrophage, IL-33
Citation
Amôr NG, Santos PSS and Campanelli AP (2021) The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities. Front. Cell Dev. Biol. 9:636544. doi: 10.3389/fcell.2021.636544
Received
01 December 2020
Accepted
18 January 2021
Published
09 February 2021
Volume
9 - 2021
Edited by
Ana Karina Oliveira, National Center for Research in Energy and Materials (Brazil), Brazil
Reviewed by
Eliana Blini Marengo, Hospital Israelita Albert Einstein, Brazil; Jamile Sá, Brazilian Biosciences National Laboratory (LNBio), Brazil
Updates
Copyright
© 2021 Amôr, Santos and Campanelli.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ana Paula Campanelli, apcampan@usp.br
This article was submitted to Molecular Medicine, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.